These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 28609830)
1. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. Voss RK; Feng L; Lee JE; Perrier ND; Graham PH; Hyde SM; Nieves-Munoz F; Cabanillas ME; Waguespack SG; Cote GJ; Gagel RF; Grubbs EG J Clin Endocrinol Metab; 2017 Aug; 102(8):2807-2813. PubMed ID: 28609830 [TBL] [Abstract][Full Text] [Related]
2. All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients. Long KL; Etzel C; Rich T; Hyde S; Perrier ND; Graham PH; Lee JE; Hu MI; Cote GJ; Gagel R; Grubbs EG Fam Cancer; 2017 Apr; 16(2):283-289. PubMed ID: 27864651 [TBL] [Abstract][Full Text] [Related]
3. Long-Term Outcomes and Aggressiveness of Hereditary Medullary Thyroid Carcinoma: 40 Years of Experience at One Center. Raue F; Bruckner T; Frank-Raue K J Clin Endocrinol Metab; 2019 Oct; 104(10):4264-4272. PubMed ID: 31145454 [TBL] [Abstract][Full Text] [Related]
4. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation. Frank-Raue K; Raue F Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387 [TBL] [Abstract][Full Text] [Related]
5. [The clinical patterns and RET proto-oncogene in fifteen multiple endocrine neoplasia type 2A pedigrees]. Zhou YL; Zhu SX; Li JJ; Liu JB; Yin M; Xiao BY; Yu CL; Wang LM; Gu LQ; Cui B; Ning G; Li XY; Zhao YJ Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):466-70. PubMed ID: 17663821 [TBL] [Abstract][Full Text] [Related]
6. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. Thosani S; Ayala-Ramirez M; Palmer L; Hu MI; Rich T; Gagel RF; Cote G; Waguespack SG; Habra MA; Jimenez C J Clin Endocrinol Metab; 2013 Nov; 98(11):E1813-9. PubMed ID: 24030942 [TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma. Silva AL; Carmo F; Moura MM; Domingues R; Espadinha C; Leite V; Cavaco B; Bugalho MJ Endocrine; 2015 Jun; 49(2):366-72. PubMed ID: 25725622 [TBL] [Abstract][Full Text] [Related]
11. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma. Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696 [TBL] [Abstract][Full Text] [Related]
12. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. D'Aloiso L; Carlomagno F; Bisceglia M; Anaganti S; Ferretti E; Verrienti A; Arturi F; Scarpelli D; Russo D; Santoro M; Filetti S J Clin Endocrinol Metab; 2006 Mar; 91(3):754-9. PubMed ID: 16384843 [TBL] [Abstract][Full Text] [Related]
14. Genotype-specific development of MEN 2 constituent components in 683 RET carriers. Machens A; Lorenz K; Weber F; Brandenburg T; Führer-Sakel D; Dralle H Endocr Relat Cancer; 2024 Jul; 31(7):. PubMed ID: 38753300 [TBL] [Abstract][Full Text] [Related]
15. Revisiting the genotype-phenotype correlation in children with medullary thyroid carcinoma: A report from the GPOH-MET registry. Kuhlen M; Frühwald MC; Dunstheimer DPA; Vorwerk P; Redlich A Pediatr Blood Cancer; 2020 Apr; 67(4):e28171. PubMed ID: 31925938 [TBL] [Abstract][Full Text] [Related]
16. Novel RET mutations in macedonian patients with medullary thyroid carcinoma: genotype-phenotype correlations. Jovanovic R; Kostadinova-Kunovska S; Janevska V; Bogoeva B; Spasevska L; Miladinova D; Ugrinska A; Zdraveska-Kochovska M; Trajkov D; Petrusevska G Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):93-107. PubMed ID: 26076779 [TBL] [Abstract][Full Text] [Related]
17. Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study. Mathiesen JS; Habra MA; Bassett JHD; Choudhury SM; Balasubramanian SP; Howlett TA; Robinson BG; Gimenez-Roqueplo AP; Castinetti F; Vestergaard P; Frank-Raue K J Clin Endocrinol Metab; 2017 Jun; 102(6):2069-2074. PubMed ID: 28323957 [TBL] [Abstract][Full Text] [Related]
18. A Homozygous RET K666N Genotype With an MEN2A Phenotype. Jaber T; Hyde SM; Cote GJ; Grubbs EG; Giles WH; Stevens CA; Dadu R J Clin Endocrinol Metab; 2018 Apr; 103(4):1269-1272. PubMed ID: 29408964 [TBL] [Abstract][Full Text] [Related]
19. A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma. Opsahl EM; Brauckhoff M; Schlichting E; Helset K; Svartberg J; Brauckhoff K; Mæhle L; Engebretsen LF; Sigstad E; Grøholt KK; Akslen LA; Jørgensen LH; Varhaug JE; Bjøro T Thyroid; 2016 Sep; 26(9):1225-38. PubMed ID: 27400880 [TBL] [Abstract][Full Text] [Related]
20. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Yip L; Cote GJ; Shapiro SE; Ayers GD; Herzog CE; Sellin RV; Sherman SI; Gagel RF; Lee JE; Evans DB Arch Surg; 2003 Apr; 138(4):409-16; discussion 416. PubMed ID: 12686527 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]